Full Text View
Tabular View
No Study Results Posted
Related Studies
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes
This study has been terminated.
( The compound has a benign safety profile with short-term use, clinically sig efficacy responses have not been demonstrated, or if so, have not been sustained. )
Study NCT00458159   Information provided by Celgene Corporation

First Received on April 5, 2007.   Last Updated on August 28, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Interventions listed in this trial
Sponsors listed in this trial